A3 Adenosine Receptor Agonists as Multisystem Disease Modifiers: From Molecular Signaling to Clinical Translation

Area of Science:

• Pharmacology
• Molecular Biology
• Translational Medicine

Background:

• The A3 adenosine receptor (A3AR) is upregulated in inflamed, hypoxic, fibrotic tissues, and malignancies.
• Its unique expression pattern supports pathology-selective drug development.

Purpose of the Study:

• To review the molecular mechanisms and therapeutic potential of A3AR activation.
• To highlight A3AR agonists as a unifying therapeutic strategy for various diseases.

Main Methods:

• Review of preclinical studies and clinical trial data on A3AR agonists.
• Analysis of signaling pathways regulated by A3AR activation (Gi, PLC, PI3K/Akt, NF-κB, MAPKs, Wnt/β-catenin).

Main Results:

• A3AR agonism demonstrates anti-cancer, anti-fibrotic, immunomodulatory, neuroprotective, and organ-protective effects.
• Piclidenoson and namodenoson show favorable safety and disease-modifying activity in clinical programs.
• A3AR activation suppresses inflammation, pathological cell survival, and protects stressed tissues.

Conclusions:

• A3AR activation is a unifying therapeutic principle for diseases involving inflammation, hypoxia, and oxidative stress.
• Selective A3AR agonists represent first-in-class agents with broad clinical applicability.
• Targeting A3AR offers a novel approach for inflammatory, fibrotic, and oncologic indications.